Defining the anti-inflammatory activity of a potent myxomaviral chemokine modulating protein, M-T7, through site directed mutagenesis

15Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Viral chemokine modulating proteins provide new and extensive sources for therapeutics. Purified M-T7, a poxvirus-derived secreted immunomodulatory protein, reduces mononuclear cell invasion and atheroma in rodent models of angioplasty injury as well as aortic and renal transplant, improving renal allograft survival. M-T7 is a rabbit species-specific interferon gamma receptor (IFNγR) homolog, but also inhibits chemokine/glycosaminoglycan (GAG) interactions for C, CC and CXC chemokines, with cross-species specific inhibitory activity. M-T7 anti-atheroma activity is blunted in GAG deficient mouse aortic transplants, but not in CC chemokine receptor deficient transplants, supporting M-T7 interference in chemokine/GAG interactions as the basis of the atheroma-inhibitory activity. We have assessed point mutants of M-T7 both in vivo in a mouse angioplasty model and in vitro in tissue culture and binding assays, in order to better define the primary mechanism of anti-atheroma activity. Of these M-T7 mutants, the R171E and E209I M-T7 mutants lost inhibitory activity for plaque growth in hyperlipidemic ApoE-/- mice after angioplasty injury and R171E, moreover, greatly exacerbated plaque growth and inflammation. F137D retained some inhibitory activity for plaque growth. In contrast, for cell migration assays, M-T7-His6X, F137D, R171E, and E209I all inhibited CC chemokine (RANTES) mediated cell migration. For the ligand binding assays, R171E and E209I had significantly reduced binding to RANTES and IFNγ, whereas F137D retained wild-type binding activity. Heparin treatment further reduced RANTES binding of all three M-T7 mutants. In summary, point mutations of M-T7, R171E and E209I, exhibited reduced anti-inflammatory properties in vivo after mouse angioplasty with a loss of in vitro binding to RANTES and IFNγ, indicating these point mutations partially disrupt M-T7 ligand-binding activities. Unexpectedly, the M-T7 mutants all retained inhibitory activity for human monocyte THP-1 cell migration ex vivo, suggesting additional inhibitory properties against human monocyte THP-1 cells that are independent of chemokine inhibition. © 2013 Elsevier Ltd.

Cite

CITATION STYLE

APA

Bartee, M. Y., Chen, H., Dai, E., Liu, L. Y., Davids, J. A., & Lucas, A. (2014). Defining the anti-inflammatory activity of a potent myxomaviral chemokine modulating protein, M-T7, through site directed mutagenesis. Cytokine, 65(1), 79–87. https://doi.org/10.1016/j.cyto.2013.10.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free